Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 INCB123667 versus investigator's choice chemotherapy in cyclin E1-overexpressing platinum-resistant ovarian cancer
NL-OMON61062Phase 3Active, not recruiting
- Sponsor
- Incyte
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of INCB123667 in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by Incyte. Primary endpoints: Progression-free survival by blinded independent central review and Overall survival. Started Jul 2026; status: active, not recruiting.
02
Drugs
INCB123667
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NL-OMON61062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61062.